Inflammation may predict cancer drug success, study finds
NCT ID NCT07241403
First seen Nov 21, 2025 · Last updated May 14, 2026 · Updated 31 times
Summary
This study looked at 698 people with advanced colorectal cancer to see if inflammation in the body changes how well a targeted therapy (bevacizumab) combined with chemotherapy works. Researchers measured inflammation markers in the blood and tracked survival and tumor response. The goal was to find clues that could help predict which patients benefit most from this treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The second hospital of Nanchang university
Nanchang, Jiangxi, 330006, China
Conditions
Explore the condition pages connected to this study.